Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 USD | 0.00% | +20.00% | -86.75% |
Apr. 17 | Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating | MT |
Apr. 16 | Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2 | MT |
Financials (USD)
Sales 2024 * | 41.06M | Sales 2025 * | 62.09M | Capitalization | 79.09M |
---|---|---|---|---|---|
Net income 2024 * | -133M | Net income 2025 * | -93M | EV / Sales 2024 * | 1.93 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.27 x |
P/E ratio 2024 * |
-0.65
x | P/E ratio 2025 * |
-1.09
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.02% |
Latest transcript on Marinus Pharmaceuticals, Inc.
1 week | +20.00% | ||
Current month | -84.07% | ||
1 month | -83.65% | ||
3 months | -85.53% | ||
6 months | -78.02% | ||
Current year | -86.75% |
Managers | Title | Age | Since |
---|---|---|---|
Scott Braunstein
CEO | Chief Executive Officer | 60 | 18-09-04 |
Steven Pfanstiel
DFI | Director of Finance/CFO | 51 | 21-04-11 |
Joseph Hulihan
CTO | Chief Tech/Sci/R&D Officer | 68 | 19-11-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Mayleben
BRD | Director/Board Member | 63 | 08-11-30 |
Scott Braunstein
CEO | Chief Executive Officer | 60 | 18-09-04 |
Elan Ezickson
BRD | Director/Board Member | 60 | 19-12-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.96% | 11 M€ | -6.03% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 1.44 | 0.00% | 1,507,132 |
24-04-23 | 1.44 | -2.37% | 2,871,897 |
24-04-22 | 1.475 | +6.88% | 3,257,216 |
24-04-19 | 1.38 | -2.13% | 2,618,548 |
24-04-18 | 1.41 | -2.08% | 4,841,039 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.75% | 79.09M | |
+25.61% | 672B | |
+25.87% | 570B | |
-5.24% | 360B | |
+16.49% | 321B | |
+8.28% | 300B | |
+7.09% | 217B | |
-9.12% | 204B | |
+5.01% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- MRNS Stock